^
    3ms
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). (clinicaltrials.gov)
    P3, N=186, Active, not recruiting, Biofrontera Bioscience GmbH | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    3ms
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults (clinicaltrials.gov)
    P2, N=126, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    4ms
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=165, Recruiting, Biofrontera Bioscience GmbH | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Ameluz (aminolevulinic acid)
    5ms
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Recruiting, Case Comprehensive Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2023
    Enrollment open • Trial initiation date
    |
    Ameluz (aminolevulinic acid)
    7ms
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Case Comprehensive Cancer Center | Initiation date: Sep 2023 --> Mar 2024
    Trial initiation date
    |
    Ameluz (aminolevulinic acid)